Sanofi recently announced that it received an approval for the sale and marketing of its dengue vaccine in Philippines.
The tetravalent dengue vaccine, Dengvaxia, was approved by the Philippines’ Food and Drug Administration for the prevention of disease caused by all four dengue types in individuals from 9-45 years of age living in endemic areas.
Dengue is the fastest growing mosquito-borne disease in the world today, causing nearly 400 million infections every year, according to the World Health Organization (WHO).
“Approval of the first dengue vaccine in Asia, which bears 70% of global disease burden, is a major milestone in dengue prevention and public health,” Sanofi Pasteur President and CEO Olivier Charmeil said in a statement.
Dengue is a growing health threat to many tropical and subtropical countries in Latin America and Asia. The disease is growing worldwide due to factors such as increased urbanization, mobility of populations and climate changes. In Asia, dengue fever burden continues to be the highest globally with an estimated 67 million people being sickened by the dengue annually.
Dengue is an urban disease that attacks populations of Asia in the form of unpredictable outbreaks capable of paralyzing health care systems, negatively impacting social and economic activity. Asian endemic countries are spending an estimated $6.5 billion annually in both direct medical and indirect costs due to dengue.
As we reported, Mexico is the world’s first country to approve Dengvaxia drug for the prevention of dengue. Earlier this month, Mexican’s Federal Commission for the Protection against Sanitary Risks approved Dengvaxia, based on a clinical development program involving over 40,000 people of different ages in 15 countries.